gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VSTMHealthcarePharmaceuticals

Verastem, Inc. (VSTM)

$8.65−6.28%
Close Oct 16, 2026 · split-adjusted
Oct 16, 2026$8.65▼ 9.04% in range
Oct 16, 2025Low $3.45 · High $10.64Oct 16, 2026
What changed · written from our data
As of Oct 16, 2026

Verastem closed at $8.65 on Oct 16, down 6.28%, 18.7% below its 52-week closing high. Volume of 6.1M shares was 1.23× its 20-day average (close to normal).

Split-adjusted performance: +14.6% over one month, +31.5% over six months, -8.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $40.08M, up 1775.4% from a year earlier, with a net margin of -86.5%.

Short interest was 15.0M shares at the Sep 30 settlement, down 17.0% from the prior report (17.7% of float, 7.0 days to cover).

Market cap$783.4M90.6M shares
Revenue · quarter$40.1M+1775.4% YoY
Diluted EPS$-0.35—
P/E · TTM—P/S 9.0×
Net margin-86.5%Gross 89.9%
Dividend yieldNone
52-week range3.45 – 10.64−18.7% from high
Volume6.1M1.23× 20-day avg
Volatility · 60d71.8%Annualised
Short % of float17.7%7.0 days to cover
Net cash$54.6MCash $136.4M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.2%1M +14.6%3M +50.4%6M +31.5%YTD +12.0%1Y −8.0%3Y +5.2%5Y −74.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 422 companies (100 = best)

6-month momentum90
Revenue growth96
Net margin44
Value (low P/E)—
Size67

Industry medians: 6-month return −26.8%, revenue growth +6.4%, net margin −39.7%, P/E 15.8×.

Short interest

Details →
Shares short15.0M−17.0% vs prior
Days to cover7.0Settled Sep 30
% of float17.7%
Short vol. 10d50.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VSTMVerastem$8.65−6.28%+31.5%+1775.4%−86.5%—$783.4M
ALMSAlumis$6.12−3.01%−75.5%−37.7%−8557.2%—$792.1MCompare
ARDXArdelyx$3.09−5.50%−52.1%+23.8%−13.8%—$797.8MCompare
CRVSCorvus Pharmaceuticals$9.52−3.35%−43.1%———$800.8MCompare
KURAKura Oncology$9.08−6.39%−6.2%+36.5%−327.3%—$807.8MCompare
MLTXMoonLake Immunotherapeutics$9.55−6.92%−47.9%———$812.8MCompare
COLLCollegium Pharmaceutical$23.19+0.04%−32.6%+6.3%−7.5%15.8$755.0MCompare
GERNGeron$1.17−4.88%−30.4%+17.2%−29.0%—$751.7MCompare
AVBPArriVent BioPharma$16.66−0.77%−43.8%———$821.5MCompare

News about Verastem

All news →
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?Zacks Investment Research · 5d ago▲ PositiveVerastem Stock Skyrockets 121% in 3 Months: Here Is WhyZacks Investment Research · Sep 8, 2026▲ Positive

Quick answers

What does Verastem do?
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
What is VSTM's market cap?
$783.37M, based on the Oct 16 close of $8.65.
Does Verastem pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VSTM is sold short?
15.0M shares, 17.7% of float, as of Sep 30, 2026.
What sector is VSTM in?
Healthcare, in the Pharmaceuticals industry.

About Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

HQ: Needham, MA102 employeesListed Jan 27, 2012verastem.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology